Iwamoto R, Handa K, Mekada E
Institute of Life Science, Kurume University, Kurume, Fukuoka 839-0861, Japan.
J Biol Chem. 1999 Sep 3;274(36):25906-12. doi: 10.1074/jbc.274.36.25906.
Heparin-binding epidermal growth factor-like growth factor (HB-EGF) transduces mitogenic signals through the EGF receptor (EGFR). There are two forms of HB-EGF, the membrane-anchored form (pro-HB-EGF) and the soluble form (sHB-EGF). We studied the biological activity of pro-HB-EGF by using a model in which pro-HB-EGF-expressing effector cells was co-cultured with EGFR-expressing target cells. The DER cell, an EGFR-expressing derivative of the interleukin-3-dependent hematopoietic 32D cell line, grows well in the presence of EGF or sHB-EGF without IL-3. When DER cells were co-cultured on a monolayer of Vero-H cells overexpressing pro-HB-EGF, growth inhibition and subsequent apoptosis were induced in the DER cells even in the presence of excess amounts of EGF or sHB-EGF. Such growth inhibition of DER cells was abrogated when specific antagonists for pro-HB-EGF were added in the culture medium or when direct contact of DER cells with Vero-H cells was prevented, indicating that pro-HB-EGF is involved in this inhibitory effect. Pro-HB-EGF-induced apoptosis of DER cells was also observed even in the presence of IL-3. This rules out the possibility of simple competition between soluble EGFR ligands and pro-HB-EGF. Moreover, 32D cells expressing EGFR mutant composed of the extracellular and the transmembrane domain of EGFR and the cytoplasmic domain of erythropoietin receptor did not undergo apoptosis by co-culture with Vero-H cells, indicating that the inhibitory signal induced by pro-HB-EGF-expressing Vero-H cells is mediated to DER cells via EGFR and that the cytoplasmic domain of EGFR is essential for pro-HB-EGF-induced apoptosis. From these results, we concluded that pro-HB-EGF has unique biological activity through cell-cell contact that is distinct from the activity of sHB-EGF.
肝素结合表皮生长因子样生长因子(HB-EGF)通过表皮生长因子受体(EGFR)转导促有丝分裂信号。HB-EGF有两种形式,膜锚定形式(前体HB-EGF)和可溶性形式(sHB-EGF)。我们通过使用一种模型来研究前体HB-EGF的生物学活性,在该模型中,表达前体HB-EGF的效应细胞与表达EGFR的靶细胞共培养。DER细胞是白细胞介素-3依赖性造血32D细胞系的一种表达EGFR的衍生物,在有EGF或sHB-EGF而无IL-3的情况下生长良好。当DER细胞在过表达前体HB-EGF的单层Vero-H细胞上共培养时,即使存在过量的EGF或sHB-EGF,DER细胞也会受到生长抑制并随后发生凋亡。当在培养基中加入前体HB-EGF的特异性拮抗剂或阻止DER细胞与Vero-H细胞直接接触时,DER细胞的这种生长抑制作用被消除,这表明前体HB-EGF参与了这种抑制作用。即使在有IL-3的情况下,也观察到前体HB-EGF诱导的DER细胞凋亡。这排除了可溶性EGFR配体与前体HB-EGF之间简单竞争的可能性。此外,表达由EGFR的细胞外和跨膜结构域以及促红细胞生成素受体的细胞质结构域组成的EGFR突变体的32D细胞与Vero-H细胞共培养时不会发生凋亡,这表明表达前体HB-EGF的Vero-H细胞诱导的抑制信号通过EGFR介导至DER细胞,并且EGFR的细胞质结构域对于前体HB-EGF诱导的凋亡至关重要。从这些结果中,我们得出结论,前体HB-EGF通过细胞间接触具有独特的生物学活性,这与sHB-EGF的活性不同。